-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Enzon Pharmaceuticals, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2014 to Q2 2024.
- Enzon Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $3K, a 94.1% decline year-over-year.
- Enzon Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$170K.
- Enzon Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$157K, a 22.3% increase from 2022.
- Enzon Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$202K.
- Enzon Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2018 was $0.000, a 100% decline from 2017.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)